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Cannabidiol Reduces Leukemic Cell
Size – But Is It Important?
Nikoletta Kalenderoglou, Tara Macpherson and Karen L. Wright*
Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK
The anti-cancer effect of the plant-derived cannabinoid, cannabidiol, has been widely
demonstrated both in vivo and in vitro. However, this body of preclinical work has
not been translated into clinical use. Key issues around this failure can be related to
narrow dose effects, the cell model used and incomplete efficacy. A model of acute
lymphoblastic disease, the Jurkat T cell line, has been used extensively to study the
cannabinoid system in the immune system and cannabinoid-induced apoptosis. Using
these cells, this study sought to investigate the outcome of those remaining viable cells
post-treatment with cannabidiol, both in terms of cell size and tracking any subsequent
recovery. The phosphorylation status of the mammalian Target of Rapamycin (mTOR)
signaling pathway and the downstream target ribosomal protein S6, were measured.
The ability of cannabidiol to exert its effect on cell viability was also evaluated in
physiological oxygen conditions. Cannabidiol reduced cell viability incompletely, and
slowed the cell cycle with fewer cells in the G2/M phase of the cell cycle. Cannabidiol
reduced phosphorylation of mTOR, PKB and S6 pathways related to survival and cell
size. The remaining population of viable cells that were cultured in nutrient rich conditions
post-treatment were able to proliferate, but did not recover to control cell numbers.
However, the proportion of viable cells that were gated as small, increased in response to
cannabidiol and normally sized cells decreased. This proportion of small cells persisted
in the recovery period and did not return to basal levels. Finally, cells grown in 12%
oxygen (physiological normoxia) were more resistant to cannabidiol. In conclusion, these
results indicate that cannabidiol causes a reduction in cell size, which persists post-
treatment. However, resistance to cannabidiol under physiological normoxia for these
cells would imply that cannabidiol may not be useful in the clinic as an anti-leukemic
agent.
Keywords: cannabidiol, Jurkat, cell size, ribosomal protein S6, leukaemia, protein kinase B, physiological
normoxia
INTRODUCTION
The anti-cancer potential of the phytocannabinoids has been of great interest for the past couple
of decades. The non-psychoactive nature of cannabidiol (CBD), has prompted many studies, both
in vivo and in vitro, that support a role for CBD in tumor regression and inhibition of cell viability
through reactive oxygen species (ROS)-driven and caspase-dependent apoptosis (reviewed by
McAllister et al., 2015). However, the anti-cancer potential of CBD has not been translated into
the clinic. A few reasons for this have been asserted, such as incomplete growth inhibition and less
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than optimal assay conditions (oxygen levels, presence of
serum, monocultures) (Fowler, 2015). In addition, the narrow
therapeutic window for CBD might be prohibitive (Massi
et al., 2013) and, although multidrug therapy could be a
solution, drug interactions and metabolism would require further
careful analysis. However, one study showed a dose-dependent
management of acute lymphoblastic leukemia in one patient with
oral cannabinoid extracts (Singh and Bali, 2013). The dose of
CBD in this study was not clearly defined.
The Jurkat leukaemic T-cell line is one of the best known
model systems for T-cell receptor (TCR) signaling and T-cell
acute lymphoblastic leukemia (ALL) since they were purified
from a 14 year old patient (Schneider et al., 1977). They have also
been used extensively to explore the role of cannabinoids in the
immune system, particularly since expression of the cannabinoid
receptor-1 (CB1) is absent in these cells (Bouaboula et al., 1993)
and can be upregulated through activation (Daaka et al., 1996)
and by the phytocannabinoid 19-tetrahydrocannabinol (THC)
(Jia et al., 2006; Börner et al., 2007). This absence subsequently
revealed an important role for the CB2 receptor in apoptosis
of malignant lymphoblasts (McKallip et al., 2002). However,
aberrant CB2 receptor signaling in Jurkats, both in terms of
adenylate cyclase inhibition (Schatz et al., 1997) and intracellular
calcium mobilization (Rao et al., 2004), has rendered these cells
useful for identifying non-cannabinoid receptor effects. Indeed,
this was shown for the endogenous cannabinoid, anandamide
(AEA), such that the induced apoptosis in Jurkats was via a
membrane lipid raft mechanism and not via vanilloid (TRPV)-
1 or CB1/2 receptors (Sarker and Maruyama, 2003). This
was similarly true for the CB1/VR1 hybrid molecule, arvanil,
in that induced apoptosis was non-receptor mediated and
largely via the intrinsic pathway with some involvement of the
plasma membrane NADH-oxido-reductase system (Sancho et al.,
2003).
Subsequent studies using this cell line and THC, established
the intrinsic pathway of apoptosis as being critical (Lombard
et al., 2005), but, importantly, that the CB2 receptor did in
fact mediate this effect through an increase in p38 MAPK
activity (Herrera et al., 2005) and ceramide production
(Herrera et al., 2006) and/or through a reduction in the
Raf-1/MEK/ERK signaling pathway (Jia et al., 2006). With
respect to CBD, a meticulous study of CBD-induced
apoptosis revealed a dependence on the CB2 receptor for
the expression of the NAD(P)H oxidases p22phox and Nox4,
ROS production and caspase activation (McKallip et al.,
2006).
In this study, we sought to explore the issue of incomplete
cell death in Jurkat T cells in response to CBD. Inhibition
of survival and cell growth pathways by cannabidiol revealed
a potential role for the ribosomal S6 protein, which has
been reported to be a key regulator of cell size independent
of its role in protein translation (Ruvinsky et al., 2005).
We then questioned whether CBD had an impact on cell
size and, if so, whether it was reversible. To strengthen
the translatability of these findings, we also checked whether
physiological normoxia altered the cannabidiol effect on cell
viability.
MATERIALS AND METHODS
Drugs and Reagents
Cannabidiol was obtained from Tocris Bioscience (Bristol, UK).
CBD was initially dissolved in DMSO (stock concentration of
75 mM) with subsequent dilutions in serum-free tissue culture
medium for in vitro experiments. Doxorubicin hydrochloride
was purchased from Abcam (Cambridge, UK) and the stock
dilution in DMSO to 25 mM was diluted in serum-free medium.
The following antibodies were purchased from Cell Signaling
Technology [New England Biolabs (NEB), Hertfordshire, UK]:
PathScan R© Multiplex Western Cocktail I (#5301), anti-Phospho-
mTOR (Ser2448) (D9C2) XP R© Rabbit mAb (#5536), β-Actin
(8H10D10) Mouse mAb (#3700), anti-Rabbit IgG, HRP-linked
Antibody (#7074) and anti-Mouse IgG, HRP-linked Antibody
(#7076). Concanavalin A was from Sigma–Aldrich, UK (#C2272)
with stock solutions stored at 5 mg/mL in dH2O.
Cells
The human leukaemic cell line Jurkat were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum
(complete medium defined as nutrient rich conditions) (both
from Invitrogen, Paisley, UK). For routine culture, medium was
changed every 2–3 days and cell density was maintained between
5 × 105 and 2 × 106 cells/mL. Standard incubator conditions
were 21% O2, 5% CO2, and 37◦C, denoted AtmosO2. Serum-
free medium (defined as nutrient poor conditions) was used in
signaling experiments and to initiate the CBD effect in recovery
experiments, with complete medium used in the recovery phase.
Cells were also cultured in physiological normoxia (12% O2
and 5% CO2, denoted PhysO2) in an H35 Hypoxystation
from Don Whitley Scientific, Shipley, UK. Normal cell culture
used 5% serum-containing RPMI. For activation experiments,
106 cells/mL from both AtmosO2 and PhysO2 were washed
once with RPMI and cultured in normal growth medium
supplemented with 5 µg/mL Concanavalin A for 48 h.
Viability Assays
Exponentially proliferating cells were counted and 105 cells/mL
were seeded into 96-well plates in medium containing 10, 5 or
1% serum, as indicated. Cells were incubated for 72 h with or
without compounds, as indicated. After the time period, 20 µL
of PrestoBlue R© reagent (Invitrogen, Paisley, UK) was added to
wells and cells further incubated for 2 h. Changes in fluorescence
were measured at 560 and 590 nm. For doxorubicin experiments,
cells were incubated for 72 h in 5% serum conditions in both
AtmosO2 and PhysO2. All experimental values were determined
from triplicate or quadruplicate wells. After subtracting the
average fluorescence values of the no-cell control wells from all
the experimental wells, the data was averaged and depicted as a
percentage of untreated control.
Determination of Cell Size
Viable cells exclude trypan blue, whereas dead and
dying/apoptotic cells are able to take up the dye since their
membranes are compromised. Normally cultured viable Jurkat
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cells are between 10 and 14 microns (Rosenbluth et al., 2006).
Using an automated cell counter TC20 (Bio-Rad), small cells
were regarded as those within 5–9 microns and only those
that excluded trypan blue were counted. Cells greater than 14
microns were also present, but in negligible numbers, that did
not change. Giant cells greater than 18 microns were rare in
normal culture. Viability experiments were carried out in 6-well
plates and starting cell densities were always 106 cells/mL. After
treatments and times, as indicated, cells were resuspended and
aliquots were counted in 1:1 trypan blue (0.4%) solutions within
1–2 min to avoid toxicity. Whole cell counts were recorded as
live cells/mL and percentage viability, with subsequent gating
for live small cell counts (S) and live normal size cell counts (N),
based on the above parameters. These counts were expressed as a
percentage of the total live cell count or as cells/mL as indicated.
In addition, cell aliquots stained with 1:1 trypan blue (0.4%) were
placed on microscope slides and coverslips were applied. Phase
contrast images of the slides were acquired using a VisiCam
TC10 tablet (VWR International, Leicestershire, UK) fitted onto
a Motic BA210 Upright Microscope (Motic, Hong Kong) with a
20× objective lens.
Recovery Experiments
Proliferating cells from culture were resuspended in serum-free
RPMI medium at 106 cells/mL and treated with or without CBD
at 10 µM for 24 h. Cells were counted and resuspended in
complete medium (106 cells/mL) without CBD for a further 24 h.
This was repeated for two more rounds up to 96 h (72 h post-
treatment). In other experiments, cells were allowed to recover
for 24 h and then CBD treated again for 24 h, with a subsequent
24 h recovery.
SDS-PAGE and Immunoblotting
Cells from experiments (adjusted to 106 cells) were lysed at the
times indicated in 100 µL of PierceTM IP Lysis Buffer (#87787)
with HaltTM Protease Inhibitor Cocktail (#78430), both from
Thermo Scientific, UK. Lysates were boiled under reducing
conditions in 4X Laemmli sample buffer (Bio-Rad, Hertfordshire,
UK). Sample proteins were separated using precast 4–16% TGX
Stain-Free gels and transferred onto nitrocellulose membrane
(Bio-Rad, Hertfordshire, UK) before blocking with 5% bovine
serum albumin (BSA) in Tris-buffered saline with 0.1% Tween
(TBST) at RT for 1 h. Primary antibodies were incubated
overnight at 4◦C as per manufacturer’s instructions and, after
washing membranes in TBST, blots were incubated with the
appropriate secondary antibody at RT for 1 h. Blots were exposed
using ClarityTM Western ECL Substrate and imaged with the
Bio-Rad ChemiDocTM XRS system. Quantitation of blots was
derived from the imaging system from which the relative amount
of protein to Rab11 was calculated and used for normalization.
Flow Cytometry
Distribution of cells in the cell cycle was determined by
propidium iodide (PI) staining and flow cytometry analysis
using a FACS Canto II (BD Biosciences, Oxford, UK). Briefly,
106 cells from experiments were fixed in 90% ethanol, washed
and resuspended in RNase A (10 µg/mL) and PI (50 µg/mL).
Ten thousand events were collected and live cells were gated
away from dead cells as well as debris based on the FSC/SSC
parameters. This cell population gate is then placed on PE-Width
versus PE-Area dot plot to exclude clumped cells from single cells.
The mean FSC-H of the single cells was determined as a measure
of relative cell size. Data from the flow cytometry measurements
were analyzed using the CytExpert software (Beckman Coulter,
Buckinghamshire, UK).
Statistical Analysis
Data are expressed as the mean ± SD of n experiments.
To determine statistical significance, Student’s t-test was used
for comparing a single treatment mean with a control mean,
and a one-way ANOVA followed by a Dunnett’s multiple
comparisons test was used for analysis of multiple treatment
means. P-values< 0.05 were considered significant.
RESULTS
Effect of Cannabidiol on viability and Cell
Cycle in Jurkat Cells
Previous studies have indicated that CBD effects are influenced
by the presence of serum, and previous data on Jurkat cells
were generated in serum-free conditions (McKallip et al., 2006).
To validate previous findings, Jurkat cells were exposed to
cannabidiol (0.01–10 µM) for 72 h in a range of nutrient
conditions (Figure 1A). This resulted in a significant inhibitory
effect on the viability of cells at concentrations greater than
1 µM in low serum conditions. This effect was dependent on the
nutrient conditions since only 10 µM of CBD was able to inhibit
cellular respiration in nutrient rich conditions. IC50 values of
6.4 ± 2.9 and 2.5 ± 0.2 µM were obtained for cells kept in
5 and 1% serum, respectively. To check the cell cycle status
of treated cells, cells from treatments in serum-free conditions
were removed for DNA content analysis using PI (Table 1 and
Figure 1B). Cannabidiol delayed the cell cycle when compared to
control −, with an increase in G1 cells and a reduction of cells
in the S and G2/M phases. The percentage of SubG1 cells (late
apoptosis) remained the same.
Cannabidiol Deactivates the mTOR
Pathway
Cannabidiol has previously been shown to deactivate Protein
Kinase B/Akt (PKB) and mammalian Target of Rapamycin
(mTOR) in breast cancer cells (Shrivastava et al., 2011), so we
performed a dose response over 4 h to confirm this in Jurkat
cells (Figure 2A). CBD reduced the phosphorylation levels of
PKB and the ribosomal protein S6 only at 10 µM. There did
appear to be an increase in the p42/44 MAPKs but this was
not significant. We then performed a time course with CBD for
up to 8 h (Figure 2B). For the time course, we included the
phosphorylation of mTOR to correlate with the S6 response. CBD
did deactivate mTOR to some extent, but this was not significant
with multiple comparisons. However, the deactivation of S6 was
time-dependent, reaching significance by 2 h.
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FIGURE 1 | Cannabidiol affects Jurkat cell viability and cell cycle progression. (A) Cells were treated with CBD (0–10−5 M) for 72 h in RPMI with 10% serum
(), 5% serum (u), and 1% serum (N). Cell viability was measured using the PrestoBlue R© assay. Results are expressed as average percentage viability (±SD)
relative to untreated controls, n = 3. (B) Cell cycle histograms obtained by population-based DNA content analysis using flow cytometry, see Table 1.
Recovery of Cannabidiol-Treated Cells
Next, we sought to ascertain whether cells that remain viable after
CBD treatment for 24 h in serum-free conditions, could recover
their proliferative capacity. Complete medium was replaced daily
after the CBD treatment to a density of 106 cells/mL. Using
the Trypan Blue exclusion principle, cells were counted at the
start and daily throughout the experiment (Figure 3A). Overall,
viable cell numbers were reduced by 30% when CBD was
applied at 10 µM. This effect persisted into the next day, despite
complete medium replacement, with cell numbers returning to
their starting level after 72 h recovery. However, this recovery
did not reach the same levels as untreated cells, which more than
doubled in number. At the same time, we analyzed viability, based
on live cells as a percentage of total cell count (Figure 3B). This
reflects the cell count analysis; in that cells did not entirely recover
basal viability in this time frame. To try and mimic a multiple
dosing regime, cells that were allowed to recover for 24 h and then
again treated with CBD in serum-free conditions, had a further
TABLE 1 | Cell cycle distribution.
Cell cycle stage Control + Control − CBD (10 µM)
Sub G1 2.18 ± 0.2 5.63 ± 0.6 5.14 ± 0.7
G1 70.94 ± 0.9 66.93 ± 0.9 78.21 ± 1.7∗
S 18.99 ± 0.6 15.01 ± 1.5 8.9 ± 1.5∗
G2/M 7.4 ± 1.4 12.11 ± 1.4 8.74 ± 0.8∗
Cells were cultured in complete medium (control +), serum-free medium with CBD
(10−5 M) or without (control −) for 24 h. The percentage (± SD) of cells in each
phase of the cell cycle is shown, (∗p < 0.05) n = 4.
reduction in viability to 34.2 ± 1.4 %, which did not recover
(Figure 3C).
Cannabidiol Reduces Cell Size
Since we noted the significant reduction in phosphorylation
of S6 by CBD and had observed smaller cells in normal cell
counts visualized under the microscope (Figure 4B, left panel),
we checked the actual cell size change using automated multifocal
plane analysis of cells gated for size. Gating was based on
previous evidence (Rosenbluth et al., 2006) and we found that
in cycling asynchronous cultures, the percentage of so-called
small cells increases as cell density increases (Figure 4A). It
should be emphasized here that these small cells are not dead or
dying cells; they exclude Trypan Blue and are usually counted
as viable in total cells counts (which takes into account all
viable cells, regardless of size). Treated cells were also imaged
(Figure 4B) and analyzed using flow cytometry (Figures 4C,D).
Cells were cultured in nutrient rich medium (10% serum, control
+), serum-free medium (control −) and with CBD (10 µM)
in serum-free medium for 24 h (Figures 4B–D). The images
in Figure 4A show the small cells seen by eye. However, the
mean FSC-H, which is a measure of relative cell size based
on the granularity of cells, was found to be significantly less
in cells in serum-free medium compared to normal culture
conditions (Figure 4D). More importantly, CBD further reduced
the mean FSC-H, seen as a left-shift in the histogram in
Figure 4C and quantified in Figure 4D. Performing the
recovery experiment (see Figure 3B) and automated multifocal
plane analysis, we found that CBD significantly increased the
percentage of small cells over that of control (Figure 4E)
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FIGURE 2 | Cannabidiol-induced mTOR and S6 dephosphorylation.
(A) Representative blots of CBD dose response (10−5–10−8 M) on PKB,
p42/44, and S6 phosphorylation, top panel. CTL denotes cells treated with
vehicle alone. (B) Time course up to 8 h of S6 and mTOR phosphorylation
with and without CBD (10−5 M), top panel. Bottom panels show the intensity
of protein bands normalized to Rab11, calculated as fold difference from
controls (mean ± SEM), n = 3 (∗p < 0.05).
and that despite medium replenishment, this population ratio
persisted.
Physiological Normoxia Renders Cells
Resistant to CBD
To try and replicate these results and potentially explore further
mechanisms for our results, we sought to improve our cell model
to more closely reflect model the in vivo conditions that Jurkat
T cells originated from. Cells were transferred and cultured in
complete medium in an environment-controlled incubator at
12% O2 (termed PhysO2). Whilst T cells can be found in a wide
FIGURE 3 | Recovery from cannabidiol treatment. 106 cells/mL were
treated with or without CBD (10−5 M) for 24 h in serum-free medium,
resuspended in complete medium without CBD at a density of 106 cells/mL
for 24 h. This was repeated at 48 h for a further 24 h. Cells were counted daily
(A) and viability calculated (B), UC denotes untreated control. In one set of
experiments, CBD (10−5 M) was reapplied at 48 h in serum-free medium and
allowed to recover for 24 h in complete medium without CBD (C). Viability is
expressed as the percentage of live cells in a total cell count, n = 3.
range of oxygen environments in the body, arterial blood is at
12% (Atkuri et al., 2007). Doxorubicin (Dox) is a drug used to
treat many types of cancer and is approved for use in ALL. It
is an anthracycline antibiotic and has previously been shown to
induce apoptosis in Jurkat cells (Finlay et al., 1986; Mendivil-
Perez et al., 2015). In our hands, Dox reduced cell viability with
an IC50 = 200.8 ± 24.4 nM (u) in standard culture conditions
(AtmosO2) (Figure 5A). In combination () with a sub-lethal
dose of CBD (5 µM) (N), there was a significant reduction in the
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FIGURE 4 | Cell size distribution. Cells in routine culture at different densities were counted and size-gated (A). Cells in complete medium (control +), or serum-free
medium in the absence (control –) or presence of CBD, were incubated for 24 h (B–D). (B) Representative phase contrast microscope images of cells stained with
Trypan Blue, with arrows indicating small viable cells as seen by eye. Mean FSC-H histograms (C) with quantitation (D), (∗p < 0.05) n = 4. (E) Cells from recovery
experiments (see Figure 3B) were counted and sized daily. Data is depicted as the percentage of viable small cells in the viable parent population, (∗p < 0.05) n = 3.
AUC by approximately a third (Figure 5A, inset). However, this
was only an additive effect at low concentrations of Dox that did
nothing alone (10−7–10−8 M), and the level of reduced viability
seen in this range was the same as CBD alone (∼40% reduction).
Next, performing the dose responses to Dox and CBD in PhysO2
conditions (Figure 5B), revealed a resistance to CBD alone (),
and an increased susceptibility to Dox (IC50 = 46.7 ± 6.7 nM)
(u). Compare this with an IC50 of 200 nM seen in AtmosO2
conditions. In addition, there was no additive or synergistic effect
of CBD in combination with Dox (N).
We found this surprising and sought to verify the lack
of response to CBD by performing a dose response up to
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FIGURE 5 | Physiological normoxia impacts on Jurkat cell sensitivity to cannabidiol. Cells from either AtmosO2 (A) or PhysO2 (B) cultures were seeded into
96-well plates (105 cells/well) in medium (with 5% serum) with or without CBD (5 or 10 µM, indicated as CBD5 or CBD10) and/or DOX (10−5–10−8 M) for 72 h. Cell
viability was measured using the PrestoBlue R© assay. Results are expressed as average percentage viability (±SD) relative to untreated controls. Area under the
curve (AUC) analysis (inset in A) (∗p < 0.05), n = 3. An increased dose response was performed with CBD up to 300 µM on both activated and non-activated cells
from PhysO2 conditions in medium with 5% serum (C) or 1% serum (D), n = 4.
300 µM. In 5% serum conditions, Jurkat cells did respond
to CBD, but only at concentrations greater than 37.5 µM
with an IC50 = 43.4 ± 5.1 µM (u) (Figure 5C). Since Jurkat
cells are T cells and can be activated by mitogen (Daaka
et al., 1996), we wondered whether this phenotype would
respond to CBD. Activated cells responded to CBD in the
same way as non-activated cells in the AtmosO2 environment
(data not shown) but in the PhysO2 environment, these
cells are also resistant to CBD effects up to 37.5 µM
(Figure 5C) (). Interestingly, the interaction effect between the
activated and non-activated cells are statistically significant,
with activated cells more resistant to CBD-induced cell death
(IC50 = 63.4 µM). Our earlier result (Figure 1A) showed that
1% serum conditions produced a robust dose-dependent CBD-
induced reduction in cell viability over 72 h and the serum-
free effects of CBD on Jurkats was also previously shown by
McKallip et al. (2006). We then repeated these experiments
in 1% serum conditions with both activated and non-activated
cells cultured in the PhysO2 environment (Figure 5D). Under
these conditions, there are three significant features. The
first is that CBD does reduce cell viability in both cell
phenotypes in a dose-dependent manner. Second, the low serum
conditions make a difference to the CBD-induced response
for both phenotypes and the IC50 for non-activated PhysO2
cells (3.2 µM) compares favorably with the AtmosO2 cells
in Figure 1A (2.5 µM). Third, the interaction effect is highly
significant, in that activated cells in PhysO2 conditions are
significantly more resistant to CBD than non-activated cells
(IC50 = 10.9 µM).
DISCUSSION
In this study, we found that CBD induced a reduction in
cell viability, both in terms of a reduction in mitochondrial
respiration and in overall cell number. However, of the remaining
viable cell population, there was an increase in the percentage of
small cells, which was not reversible on the return of favorable
nutrient conditions. In addition, we found that Jurkat cells
cultured in physiological conditions (PhysO2) were resistant to
CBD alone up to 40 µM, but did respond to the chemotherapeutic
agent doxorubicin. Finally, we found that low serum did reveal a
dose-dependent effect on both activated cells and non-activated
cells in the PhysO2 environment, with activated cells more
resistant to CBD.
The low efficacy of CBD in serum was first noticed when the
antibacterial activity seen in vitro was reduced 10-fold in serum
(Van Klingeren and Ten Ham, 1976). It is thought to be a result
of binding to albumin (Papa et al., 1990), but how this affects
CBD binding at the membrane is complex. The effect could also
be related to cellular stress and different mitochondrial activity
under the different nutrient conditions (Jacobsson et al., 2000;
McKallip et al., 2002, 2006).
The possibility that anti-cancer medicines might be less
effective under nutrient rich conditions is not new and interest in
low nutrient stress conditions for chemotherapeutic drug delivery
is currently in clinical trial (Lee et al., 2012; Dorff et al., 2016).
Our observation that CBD becomes considerably more effective
at killing cancer cells under these conditions in vitro supports
this view. However, recovery experiments in which cells that
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remained viable after CBD treatment in serum-free conditions
began to recover their numbers after a few days, would suggest
that incomplete cell death might carry a risk of re-emergence of
the leukemia. Repeated doses could have potential, although we
did not explore this further in the AtmosO2 environment since
we wanted to improve on this model.
The reduction in viability by CBD in serum-free conditions
had a significant impact on cell size, as measured by flow
cytometry and multifocal plane analysis. The reduction in cell
size by CBD did not appear to be reversible and the percentage
of small cells of the total viable population persisted. The
shift to a small cell phenotype may be related to hypodiploid
cells, which are a subtype of ALL (Holmfeldt et al., 2013) and
particularly resistant to chemotherapy. However, we were unable
to differentiate between viable hypodiploid cells and those in late
apoptosis, and therefore unable to say whether therapeutic use of
CBD in ALL would carry this risk.
Phosphorylation of the ribosomal protein S6 has been shown
to regulate cell size independently of its role of S6 in translation,
which does not require phosphorylation (Ruvinsky et al., 2005).
Jurkat T cells have defective lipid phosphatases, Src homology 2
domain containing inositol polyphosphate phosphatase (SHIP)
(Freeburn et al., 2002) and phosphatase and tensin homolog
deleted on chromosome 10 (PTEN) (Shan et al., 2000), resulting
in constitutive phosphorylation of PKB. Despite these defective
pathways, CBD was able to deactivate PKB at 10 µM and this
would support the loss of viability. The mTOR signaling pathway
is quite complex with phosphorylation status of mTORC1
vs. mTORC2 not explored in our study. PKB is upstream
of mTORC1 and mTORC2 is upstream of PKB. Our data
appeared to show a reduction in mTOR phosphorylation overall,
however, the analysis was not significant. However, the significant
deactivation of S6 by CBD would suggest the PKB/mTORC1
route. This deactivation effect phenocopies the rapamycin effect
on Jurkat cell size (Fumarola et al., 2005). In this study,
the prototype inhibitor of the mTOR/p70 S6 kinase pathway,
rapamycin, reduced cell mass and size with slowed proliferation
and hints at CBD being an mTOR inhibitor.
Clearly, the mechanisms of this process warrant further study.
It is possible that some cells in the population do not die in
response to CBD, but rather become resistant to the apoptotic
signal by reducing their size. These smaller cells might recover
proliferative capacity when conditions are favorable, but they
may continue to be resistant to apoptosis. However, this may
be completely irrelevant if in the complex in vivo environment,
some cancer cells display CBD resistance anyway. When these
cells were transferred to physiological normoxia, they became
resistant to CBD, whether activated or not. We have previously
shown that colorectal cancer cells become more sensitive to CBD
under more appropriate environmental conditions (Macpherson
et al., 2014) and, indeed, in this study, Jurkat cells became
more susceptible to doxorubicin-induced cytotoxicity, but CBD-
induced reduction in cell viability in the PhysO2 environment
required considerable doses of CBD. Low serum conditions did
reveal the CBD effect, but activated cells were still more resistant.
Low physiological oxygen culture is thought to be important
for stem cell culture, possibly due to the amplification of
genes involved in metabolic processes (Guo et al., 2013). This
mechanism makes sense with respect to the action of CBD, in
that mitochondrial respiration changes under different oxidative
environments could impact on the ability of CBD to generate
ROS thought to be involved in CBD-induced cell death (McKallip
et al., 2006). To achieve these doses or the preferred nutrient
poor conditions in vivo, would render CBD impractical as an
anti-leukemic medicine.
CONCLUSION
The need for better in vitro modeling is of great importance in
the preclinical phase of drug development, particularly to reduce
failures at the clinical trial phase. Our data adds further support to
the assertion that CBD may not be very clinically useful in terms
of an anti-cancer medicine per se, but may have other medicinal
value yet to be clinically proven in oncology.
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